Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DraftKings Inc (DKNG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

DraftKings IncTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

DraftKings Inc vs Zimmer Biomet Holdings Inc — how do they compare? DraftKings Inc trades at $25.61 (market cap $12.58B), while Zimmer Biomet Holdings Inc trades at $95.89 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.

DKNGZBH
Market Cap
$12.58B$18.55B
Sector
Consumer CyclicalHealth
52-Week High
$48.23$107.71
52-Week Low
$20.72$79.58
Enterprise Value
$13.51B$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DraftKings Inc

DraftKings (DKNG) trades at $24.27, up 1.0% today, showing mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company achieved its first annual net profit in 2025 ($4M) after years of losses, with revenue growing to $6.05B. However, recent quarterly earnings have missed expectations, and valuation ratios remain elevated with a P/E of 246.33. Analyst sentiment remains positive with 73% buy ratings and a $34 consensus price target, representing 40% upside potential.

The outlook for DKNG hinges on successful execution in prediction markets and sportsbook growth, particularly with the upcoming NFL season. Key risks include intense competition from prediction market platforms, regulatory challenges, and the company's ability to maintain profitability after recently turning profitable. While technical indicators show near-term resistance at $25, the substantial analyst upside and improving cash flow trends suggest potential for long-term growth if execution improves.

Zimmer Biomet Holdings Inc

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DraftKings Inc

DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.

Read more on DKNG

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH